Table 2 The Baseline Demographic Characteristics and Outcome of the Development and External Validation Set
From: Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
Variables | Subgroups | Development set (n = 96) No. of patients (%) Median (range) | External validation set (n = 45) No. of patients (%) Median (range) | P value |
|---|---|---|---|---|
Outcome | Non MSE | 26 (27.1) | 12 (26.7) | 0.959 |
MSE | 70 (72.9) | 33 (73.3) | ||
Gender | Male | 46 (47.9) | 22 (48.9) | 0.914 |
Female | 50 (52.1) | 23 (51.1) | ||
Age at onset | EOMG | 62 (64.6) | 23 (51.1) | 0.096 |
LOMG | 25 (26.0) | 12 (26.7) | ||
Elderly-onset MG | 9 (9.6) | 10 (22.2) | ||
MGFA classification | II | 62 (64.6) | 21 (46.7) | 0.128 |
III | 29 (30.2) | 20 (44.4) | ||
IV | 5 (5.2) | 4 (8.9) | ||
Thymoma | No | 62 (66.0) | 32 (71.1) | 0.543 |
Yes | 32 (34.0) | 13 (28.9) | ||
Thymectomy | No | 70 (74.5) | 41 (91.1) | 0.022* |
Yes | 24 (25.5) | 4 (8.9) | ||
Worsening | No | 24 (25.0) | 7 (15.6) | 0.207 |
Yes | 72 (75.0) | 38 (84.4) | ||
Autoimmune disease | No | 86 (89.6) | 37 (82.2) | 0.222 |
Yes | 10 (10.4) | 8 (17.8) | ||
Disease duration, months | 7 (3.0–30.5) | 2 (1.0–6.0) | 0.001* | |
Anti-AChR Abs titer, nmol/L | 6 (2.6–10.3) | 8 (4.5–20.1) | 0.018* | |
Pyridostigmine dosage, mg/day | 180 (90.0–180.0) | 180 (0–210.0) | 0.528 | |
MMT score | 14 (7.0–19.0) | 50 (41.5–50)# | 0.001* | |
MG-ADL score | 5 (4.0–8.0) | 6 (4.0–9.5) | 0.151 | |
Bulbar score | 2 (1.0–3.0) | 2 (1.0–4.0) | 0.026* | |
Respiratory score | 0 (0–1.0) | 0 (0–1.0) | 0.540 | |
Limb score | 1 (0–2.0) | 0 (0–2.0) | 0.651 | |
Ocular score | 3 (1.0–4.0) | 3 (2.0–4.0) | 0.458 | |
QMG score | 11 (9.0–14.0) | 10 (7.0–16.5) | 0.485 | |
Extraocular muscle score | 3 (1.0–4.0) | 3 (2.5–4.5) | 0.068 | |
Bulbar muscle score | 0 (0–1.0) | 1 (0–3.0) | 0.001* | |
Respiratory muscle score | 0 (0–1.0) | 0 (0–1.0) | 0.357 | |
Gross motor score | 6 (4.0–8.0) | 5 (2.0–8.5) | 0.042* | |
Axial motor score | 1 (1.0–2.0) | 1 (0–2.0) | 0.097 | |